Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 26;12(12):2099-2102.
doi: 10.21037/tp-23-436. Epub 2023 Nov 30.

Fusion and flow: refining risk prediction in KMT2A-rearranged pediatric acute myeloid leukemia

Shannon E Conneely  1 , Rachel E Rau  2
Affiliations
Editorial

Fusion and flow: refining risk prediction in KMT2A-rearranged pediatric acute myeloid leukemia

Shannon E Conneely et al. Transl Pediatr. .
No abstract available

Keywords: Acute myeloid leukemia (AML); KMT2A rearranged; measurable residual disease; risk stratification.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-436/coif). R.E.R. reports consultancy and advisory board membership with Jazz Pharmaceuticals. The other author has no conflicts of interest to declare.

Comment on

References

    1. Meyer C, Burmeister T, Gröger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia 2018;32:273-84. 10.1038/leu.2017.213 - DOI - PMC - PubMed
    1. Meyer C, Larghero P, Almeida Lopes B, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia 2023;37:988-1005. 10.1038/s41375-023-01877-1 - DOI - PMC - PubMed
    1. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489-96. 10.1182/blood-2009-04-215152 - DOI - PMC - PubMed
    1. Pollard JA, Guest E, Alonzo TA, et al. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol 2021;39:3149-60. 10.1200/JCO.20.03048 - DOI - PMC - PubMed
    1. Coenen EA, Raimondi SC, Harbott J, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood 2011;117:7102-11. 10.1182/blood-2010-12-328302 - DOI - PMC - PubMed